John LaMattina

Member of the Board of Directors, Vedanta Biosciences

Dr. LaMattina is a Senior Partner at PureTech Ventures and was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc, a company where he had a 30 year career. During Dr. LaMattina’s leadership tenure Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. He is the author of numerous scientific publications and U.S. patents.  In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D”, and “Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?”. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science, the 2004 American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes, an Honorary Doctor of Science degree from the University of New Hampshire, the Just One Break, Inc. Lifetime Achievement Award, the Legal Momentum Equal Opportunity Award, the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management, and is a member of the Board of Trustees of Boston College. He received a Ph.D. in Organic Chemistry from the University of New Hampshire.